Brain Matters (Video)

As baby boomers age, an unprecedented number of people will be diagnosed with Alzheimer's disease. The economic and social impacts will be wide reaching from cost of treatment to the effect on caregivers. Maria Carrillo, PhD, Chief Science Officer, Alzheimer’s Association joins Willliam Mobley. MD, PhD to discuss what can be done and how government, industry and the Alzheimer's Association are working together on larger scale trials and innovative projects. Series: "Alzheimer’s Disease" [Health and Medicine] [Show ID: 31801]

Ara Khachaturian, PhD, chair and president of the National Biomedical Research Ethics Council joins WIilliam Mobley, MD, PhD to discuss the evolution of biomedical research in Alzheimer's disease and the ethical standards needed to maintain excellent patient care. From institutional review boards (IRB) to industry and academic partnerships, learn how we can support and maintain effective research infrastructure. Series: "Alzheimer’s Disease" [Health and Medicine] [Show ID: 31770]

Phyllis Ferrell, Vice President and Global Development Leader for

Alzheimer's Disease at Eli Lilly and Company joins William Mobley, MD, PhD to talk about the goal set forth in the National Plan to Address Alzheimer’s Disease to “prevent and effectively treat Alzheimer’s disease by 2025.” Ferrell's shares her work to make Alzheimer's dementia preventable by finding ways to slow disease progression and advocating for early diagnosis. Series: "Alzheimer’s Disease" [Health and Medicine] [Show ID: 31803]

Ara Khachaturian, PhD, chair and president of the National Biomedical Research Ethics Council joins WIilliam Mobley, MD, PhD to discuss the evolution of biomedical research in Alzheimer's disease and the ethical standards needed to maintain excellent patient care. From institutional review boards (IRB) to industry and academic partnerships, learn how we can support and maintain effective research infrastructure. Series: "Alzheimer’s Disease" [Health and Medicine] [Show ID: 31770]

Phyllis Ferrell, Vice President and Global Development Leader for

Alzheimer's Disease at Eli Lilly and Company joins William Mobley, MD, PhD to talk about the goal set forth in the National Plan to Address Alzheimer’s Disease to “prevent and effectively treat Alzheimer’s disease by 2025.” Ferrell's shares her work to make Alzheimer's dementia preventable by finding ways to slow disease progression and advocating for early diagnosis. Series: "Alzheimer’s Disease" [Health and Medicine] [Show ID: 31803]

Eric Siemers, MD, Distinguished Medical Fellow at Eli Lilly and Company joins William Mobley, MD, PhD to discuss clinical trails for Alzheimer's disease. He explains the trial design, results, and future implications of the EXPEDITION3 trial for people with with mild dementia due to Alzheimer's disease. Learn more about potential treatments in the clinical trials pipeline that may impact both the symptoms and pathologies of Alzheimer's disease. Series: "Alzheimer’s Disease" [Health and Medicine] [Show ID: 31802]

As baby boomers age, an unprecedented number of people will be diagnosed with Alzheimer's disease. The economic and social impacts will be wide reaching from cost of treatment to the effect on caregivers. Maria Carrillo, PhD, Chief Science Officer, Alzheimer’s Association joins Willliam Mobley. MD, PhD to discuss what can be done and how government, industry and the Alzheimer's Association are working together on larger scale trials and innovative projects. Series: "Alzheimer’s Disease" [Health and Medicine] [Show ID: 31801]

From neuropathology to molecular target to clinical treatments, where are we on the road to finding an effective treatment for Alzheimer's disease? Howard Feldman, MD, FRCP(C), a neurologist noted for his original research in geriatric cognitive disorders and expertise in large-scale clinical trials, walks through the latest research and shares some tips on brain health. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 31035]

From neuropathology to molecular target to clinical treatments, where are we on the road to finding an effective treatment for Alzheimer's disease? Howard Feldman, MD, FRCP(C), a neurologist noted for his original research in geriatric cognitive disorders and expertise in large-scale clinical trials, walks through the latest research and shares some tips on brain health. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Science] [Show ID: 31035]

Learn how neuroscience can transform lives and our world through the study of empathy and compassion. By increasing self-awareness through feedback paradigms, Dr. Bill Mobley of UC San Diego explains that we, as a population, can become more empathetic and compassionate.

Series: "Excerpts" [Health and Medicine] [Show ID: 31642]